newsfilter
← Latest News
GlobeNewswire·

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics' Vivasure